Company / Working Capital
4D Molecular Therapeutics, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$369.1M
FY2025
5-year range
$204.8M / $405.8M
FY2021-FY2025
Trend
-9.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $278M to $369M over the past 2 years.
Based on SEC 10-K filings.
$369M in FY2025 with a 5-year CAGR of +6.8%.
Improved from $278M to $369M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +21.7%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2025, working capital decreased 9.0% year-over-year.
- Peak working capital was recorded in FY2024.
- Lowest working capital in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $369.1M | -9.0% |
| FY2024 | $405.8M | +46.2% |
| FY2023 | $277.6M | +35.6% |
| FY2022 | $204.8M | -14.7% |
| FY2021 | $239.9M | -9.8% |
| FY2020 | $265.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026